Orion Portfolio Solutions LLC Sells 3,073 Shares of Integer Holdings Co. (NYSE:ITGR)

Orion Portfolio Solutions LLC trimmed its stake in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) by 25.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,227 shares of the medical equipment provider's stock after selling 3,073 shares during the quarter. Orion Portfolio Solutions LLC's holdings in Integer were worth $1,223,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Mather Group LLC. grew its stake in Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock worth $25,000 after buying an additional 143 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in shares of Integer during the fourth quarter valued at $27,000. R Squared Ltd bought a new position in shares of Integer during the fourth quarter worth about $44,000. Versant Capital Management Inc increased its holdings in shares of Integer by 98.4% in the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 183 shares during the period. Finally, Principal Securities Inc. lifted its position in Integer by 31.2% in the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider's stock valued at $85,000 after purchasing an additional 152 shares during the last quarter. Institutional investors own 99.29% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Oppenheimer cut shares of Integer from an "outperform" rating to a "market perform" rating in a research report on Friday, February 21st. Citigroup increased their price objective on Integer from $130.00 to $145.00 and gave the stock a "neutral" rating in a report on Wednesday, December 11th. Benchmark lifted their target price on Integer from $140.00 to $150.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Raymond James initiated coverage on Integer in a report on Friday, March 28th. They set an "outperform" rating and a $145.00 price target on the stock. Finally, Truist Financial raised their target price on shares of Integer from $147.00 to $163.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Integer presently has a consensus rating of "Moderate Buy" and a consensus target price of $148.56.

Remove Ads

Integer Trading Up 9.1 %

Shares of NYSE ITGR traded up $9.75 during mid-day trading on Wednesday, hitting $116.48. 804,082 shares of the company traded hands, compared to its average volume of 338,673. The business has a 50 day moving average of $124.83 and a two-hundred day moving average of $131.10. The stock has a market capitalization of $3.92 billion, a price-to-earnings ratio of 34.67, a PEG ratio of 1.72 and a beta of 1.09. Integer Holdings Co. has a 1 year low of $104.93 and a 1 year high of $146.36. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). The firm had revenue of $449.50 million for the quarter, compared to analysts' expectations of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. On average, sell-side analysts anticipate that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.